Sepio Capital LP Sells 1,346 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Sepio Capital LP cut its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 15.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 7,277 shares of the pharmaceutical company’s stock after selling 1,346 shares during the quarter. Sepio Capital LP’s holdings in Vertex Pharmaceuticals were worth $3,805,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Community Financial Services Group LLC acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at about $26,000. Meeder Asset Management Inc. purchased a new stake in Vertex Pharmaceuticals during the second quarter worth $26,000. Elevation Wealth Partners LLC grew its holdings in Vertex Pharmaceuticals by 103.7% in the second quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 28 shares during the last quarter. Pingora Partners LLC acquired a new stake in Vertex Pharmaceuticals in the second quarter valued at $32,000. Finally, City Holding Co. grew its holdings in Vertex Pharmaceuticals by 128.1% in the second quarter. City Holding Co. now owns 73 shares of the pharmaceutical company’s stock valued at $36,000 after purchasing an additional 41 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Canaccord Genuity Group raised their price target on Vertex Pharmaceuticals from $436.00 to $442.00 and gave the company a “hold” rating in a research report on Tuesday, August 4th. Evercore raised their price objective on Vertex Pharmaceuticals from $535.00 to $600.00 and gave the stock an “outperform” rating in a report on Wednesday, September 2nd. TD Cowen boosted their target price on shares of Vertex Pharmaceuticals from $525.00 to $550.00 and gave the company a “buy” rating in a report on Wednesday, September 23rd. Barclays raised their price objective on Vertex Pharmaceuticals from $615.00 to $617.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Finally, Daiwa Securities Group increased their price objective on shares of Vertex Pharmaceuticals from $555.00 to $556.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $579.81.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $535.17 on Friday. Vertex Pharmaceuticals Incorporated has a one year low of $403.16 and a one year high of $560.25. The business’s 50-day simple moving average is $523.15 and its 200 day simple moving average is $482.96. The stock has a market cap of $135.83 billion, a price-to-earnings ratio of 31.15, a price-to-earnings-growth ratio of 2.51 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share for the quarter, missing analysts’ consensus estimates of $4.74 by ($0.01). Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. The business had revenue of $3.33 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same quarter last year, the business earned $4.52 EPS. Vertex Pharmaceuticals’s revenue for the quarter was up 12.5% compared to the same quarter last year. On average, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 16.75 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.